MarketWatch (press release) About Stivarga(R) (regorafenib) Tablets In the United States, Stivarga is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan -based chemotherapy, an anti-VEGF therapy ... and more »
Marketwire (press release) In addition, Pexa-Vec is being evaluated in a Phase 1-2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a Phase 2a clinical trial in treatment-refractory kidney cancer ... and more »
Wall Street Journal (press release) The company pipeline includes two clinical stage products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan :floxuridine) for the treatment of ...
Sacramento Bee Vectibix was approved in the United States in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is ... and more »
Healio Stivarga was approved by the FDA in September 2012 for use in patients with metastatic colorectal cancer who had received previous therapy with fluoropyrimidine-, oxaliplatin- or irinotecan -based regimens, along with anti-VEGF or anti-EGFR treatments.
FierceBiotech Nexavar in combination with gemcitabine /cisplatin is not recommended in patients with squamous cell lung cancer. The safety and effectiveness of Nexavar has not been established in patients with non-small cell lung cancer. Nexavar can prolong the QT ... and more »
Wall Street Journal (press release) Avastin is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer in combination with intravenous 5 fluorouracil-based chemotherapy -- Avastin in combination with fluoropyrimidine- irinotecan or fluoropyrimidine ... and more »
4-traders (press release) In addition, Pexa-Vec is being evaluated in a Phase 1/2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a phase 2a clinical trial in treatment-refractory kidney cancer ... and more »
